MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 5850 participants.

Also called NCT02006069

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 5,850 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02006069
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, China, Colombia, Denmark, Finland, France, Germany, Greece, India, Israel, Italy, Lebanon, Malaysia, Malta, Netherlands, Poland, Portugal, Puerto Rico, Saudi Arabia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02006069. Randomized; single masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2021-05-30 (actual). Results posted on 2023-05-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing
Acronym
MORE CRT MPP
Condition
Heart Failure
Intervention (Device)
MPP
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct02006069
Content hash
02e075e5f4ad2274402a7e620deabc74c909fadfcc741c8d6513ea87f2492684